Publications


* co-corresponding authors; # authors contributed equally to this work

Wang, Y.; Dix, M.M.; Remsberg, J.R.; Lee, H.Y.; Kalocsay, M.; Gygi, S.P.; Vite, G.; Lawrence, R.M.; Parker, C.G.*; Cravatt, B.F.* “Expedited Mapping of the Ligandable Proteome Using Fully Functionalized Enantiomeric Probe PairsChemRxiv, 2019.

Parker, C.G.*; Cravatt, B.F.* “Chemistry Takes Center Stage for Identifying Cancer Targetability” Cell, 2018, 173, 815.

Galmozzi, A.#; Parker, C.G.#, Kok, B. P.; Cravatt, B.F.; Saez, E. “Discovery of Modulators of Adipocyte Physiology Using Fully Functionalized Fragments” Methods Mol Biol, 2018, 1787, 115.

McEnaney, P.J.*; Parker, C.G.*; Zhang, A.X.* “Antibody-Recruiting Small Molecules: Synthetic Constructs as Immunotherapeutics,” Annu Rep Med Chem, 2018, 50, 481.

Parker, C. G.*; Kuttruf, C. A.; Galmozzi, A.; Jorgensen, L.; Chein-Hung, Y.; Hermanson, D.H.; Wang, Y.; Perez, M.E.; McKerrall, S.J.; Joslyn, C. J; Duenstl, G.; Felding, J.; Saez, E.; Baran, P.S.*; Cravatt, B.F*. “Chemical Proteomics Identifies SLC25A20 as a Functional Target of the Ingenol Class of Actinic Keratosis Drugs” ACS Cent Sci, 2017, 3, 1276

Schonhoft, J.D.#; Monteiro, C.#; Plate, L.; Eisele, Y.S.; Kelly, J.; Boland, D.; Parker, C.G.; Cravatt, B.F.; Berk, J.; Sekijima, Y.; Maurer, M.; Novais, M.; Coelho, T.; Powers, E.T.; Kelly, J.W. “Peptide Probes Detect Misfolded Transthyretin Oligomers in the Plasma of Early Stage Hereditary Amyloidosis Patients” Science Translational Medicine, 2017, 9, eaam7621.

Parker, C. G.*#; Galmozzi, A.#; Wang, Y.; Correia, B. E.; Sasaki, K.; Joslyn, C. J.; Kim, A. S.; Cavallaro, C. L.; Lawrence, M.; Johnson, S. R.; Saez, E.*; Cravatt, B. F.* “Ligand and target discovery by fragment-based screening in human cells” Cell, 2017, 168, 527-541.

Featured in News and Analysis in Nature Reviews Drug Discovery, 2017, 16, 225; as a Research Highlight in Nature Protocols, 2017, 225, 52; recommended on F1000prime as being of special significance; highlighted online in Science Translational  Medicine: In the Pipeline (3/2/2017) and in Drug Discovery News; TSRI Top 10 Scientific Breakthroughs of 2017.

Parker, C.G.; Dahlgren, M.K.; Li, D.T.; Jawanda, N.; Shoda, T.; Spasov, K.A.; Domaoal, R.A.; Sutton, R.; Anderson, K.S.; Jorgensen, W.L.; Spiegel, D.A. ”Illuminating gp120–Ligand Recognition through Computationally-Driven Optimization of Antibody-Recruiting Molecules” Chemical Science, 2014, 5, 2311-2317.

Jakobsche, C.E.#; Parker, C.G.# Tao, R.N.; Kolesnikova, M.D.; Spiegel, D.A. “Comparing Activities and Prevalence of Natural Antibody Populations from Human Serum” ACS Chemical Biology2012, 7, 1139-1151.

McEnaney, P. J.#; Parker, C.G.#; Zhang, A.X.# Spiegel, D.A. “Antibody-Recruiting Molecules: An Emerging Paradigm for Engaging Immune Function in Treating Human Disease” ACS Chemical Biology2012, 7, 1139-1151.

Parker, C.G.; Domaoal, R.A.; Anderson, K.S.; Spiegel, D.A.  “An Antibody-Recruiting Small Molecule That Targets HIV gp120” J. Am. Chem. Soc., 2009, 131, 16392-16394.

This work was also featured as a spotlight in ACS Chemical Biology, 2009, 4, 975, and was highlighted online by Drug Discovery NewsPopular Science, and as ACS Noteworthy Chemistry

Garner, P.; Hu, J.; Parker, C. G.; Youngs, W. J.; Medvetz, D. "The Cu(I) Catalyzed Exo-Selective Asymmetric Multicomponent [C+NC+CC] Coupling Reaction” Tetrahedron Lett, 2007,48 3867.

Patents

Parker, C.G.; Correia, B.; Cravatt, B.F. “Photoreactive Ligands and Uses Thereof” US Provisional Patent Application(Application No. 62/447,882)

Parker. C.G.; Spiegel, D.A. “Cytotoxic-Drug Delivering Molecules Targeting HIV (CDM-h’s), Cytotoxic Activity Against the Human Immunodeficiency Virus and Methods of Use” Patent No US20150087609 (Filed 03/15/2013; Published 03/15/2015)

Parker, C.G.; Spiegel, D.A. “Bifunctional Molecules with Antibody-Recruiting and Entry Inhibitory Activity Against the Human Immunodeficiency Virus,” Patent No. WO 2011046946. (Filed 10/12/2010, Published 4/21/2011); US9562038. (Filed 11/18/2011, Published 02/07/2017